Results 201 to 210 of about 236,432 (265)
Engineered malaria antigens enable in vivo bioconjugation to submicron biopolymer particles in E. coli. Two antigens are co‐tethered at high density and defined stoichiometry. The resulting thermostable particles elicit strong, durable antibody and T‐cell responses, conferring robust protection and blocking mosquito transmission.
Nivethika Sivakumaran +10 more
wiley +1 more source
Can prothrombin time assays withstand the influence of antiprothrombin and anti-β2-glycoprotein I antibodies on the international normalized ratio? [PDF]
Vandevelde A, Devreese KMJ.
europepmc +1 more source
IBD is driven by a vicious cycle of dysbiosis, barrier dysfunction, and immune dysregulation. We developed an inulin–butyrate conjugate nanogel (IBN) that accumulates in inflamed colon and releases butyrate via microbial inulinase/esterase. The inulin shell remodels the microbiome, while localized butyrate strengthens barrier integrity and promotes ...
Nayoon Park +7 more
wiley +1 more source
Identification of alterations of immunometabolism associated with Pompe disease. [PDF]
Costa-Verdera H +17 more
europepmc +1 more source
Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract—the B Cell Side
ABSTRACT Allergic diseases are on the rise worldwide, driven by respiratory epithelial barrier dysfunction that promotes sensitization to inhalant allergens such as pollen, dust mites, pet dander, and fungal spores. These antigens trigger IgE‐mediated immune responses that lead to diseases such as allergic rhinitis (AR) and asthma.
Ola Grimsholm +9 more
wiley +1 more source
Characterization of <i>Borrelia</i>-Derived Extracellular Vesicles: Implications for Pathogenesis and Diagnostics. [PDF]
Birkaya B +14 more
europepmc +1 more source
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter +20 more
wiley +1 more source
Understanding Biologics in CRSwNP: Related Events and Insights. [PDF]
Izquierdo-Domínguez A +4 more
europepmc +1 more source
Development of predictable and high-yield CHO cell line by site-specific integration. [PDF]
Lan W +12 more
europepmc +1 more source

